New targeted drug shows early promise for Hard-to-Treat cancers

NCT ID NCT05735366

Completed Disease control Sponsor: Chugai Pharmaceutical Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-stage study tested a new drug called SAIL66 in 22 adults with advanced solid tumors that have a specific protein (CLDN6). The main goals were to check safety, find the right dose, and see if the drug can shrink tumors. While not a cure, the approach aims to control the disease in patients who have limited options.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SOLID TUMOR are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

SOLID TUMOR

Contacts and locations

Locations

Banner MD Anderson Cancer Center

Gilbert, Arizona, 85234, United States
Cancer Institute Hospital of JFCR

Tokyo, Koto Ku, 135-8550, Japan
Georgia Cancer Center at Augusta University

Augusta, Georgia, 30912, United States
MUSC Hollings Cancer Center

Charleston, South Carolina, 29425, United States
National Cancer Center Hospital

Tokyo, Chuo Ku, 104-0045, Japan
National Cancer Center Hospital East

Kashiwa, Chiba, 277-8577, Japan
Shizuoka Cancer Center

Shizuoka, Sunto-gun, 411-8777, Japan
Tennessee Oncology, PLLC

Nashville, Tennessee, 37203, United States
The University of Texas MD Anderson Cancer Center

Houston, Texas, 77030, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.